Population-based study of the effect of bivalent HPV vassination against invasive cervical cancer and CIN3+ in The Netherlands
PhD-student Marit Middeldorp
A population-based study in The Netherlands, where routine cervical cancer screening starts at age 30 years, found that bivalent HPV16/18 vaccination strongly reduced the risk of cervical cancer and CIN3+. The authors conclude that vaccine protection extends at least until age 30 years.
